SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 28.90 |
| Enterprise Value ($M) | 36.00 |
| Book Value ($M) | 26.41 |
| Book Value / Share | 3.37 |
| Price / Book | 1.09 |
| NCAV ($M) | -4.15 |
| NCAV / Share | -0.53 |
| Price / NCAV | -6.97 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.09 |
| Return on Assets (ROA) | -0.09 |
| Return on Equity (ROE) | -0.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.44 |
| Current Ratio | 3.11 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 13.89 |
| Assets | 44.45 |
| Liabilities | 18.04 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | Knudsen Ejnar A III | 5.90 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 475 | 20,170 | 2.35 | |
| 566 | 24,792 | 2.28 | |
| 3,827 | 16,795 | 22.79 | |
| 3,292 | 7,933 | 41.50 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| HOOK – HOOKIPA Pharma Inc. | HOTH – Hoth Therapeutics, Inc. |
| HRTX – Heron Therapeutics, Inc. | IKT – Inhibikase Therapeutics, Inc. |
| IMCC – IM Cannabis Corp. |
Financial data and stock pages provided by
Fintel.io